Prof. Jean-Yves Blay, MD, PhD [7505]
As we are moving from a histopathology-directed therapeutic approach to one guided by genomic alterations, can you summarize the validations — including improvements in PFS and OS — that are available for targeted therapy in cancer? (French)
From a technology perspective, why are current genomic testing models based on targeted sequencing (“Hot Spot”) unsustainable and less effective than comprehensive genomic profiling (GGP) developed by FoundationOne and other providers ...
What common mutations and genomic rearrangements—among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS—present in tumors represent the best molecular targets for cancer therapy? Are some more predictive of success with targeted therapy ...
Using FoundationONE NGS, what are the false?negative rates for EFGR? For ALK? What are the comparative false-negative rates using standard hot spot NGS panels? What explains the difference in the false-negative rates between FoundationONE ...
Do genomic alterations change as a cancer evolves? Is there a rationale for analyzing tumor samples longitudinally for genomic alterations over the course of a patient’s cancer? (French)
How do we approach the complexity of genomic alterations in specific tumor subtypes with different technologies, including FoundationOne? NGS? How do we account for co-existing genomic alterations? (French)